Studies have revealed that colchicine can significantly reduce MPO, and this effect has been demonstrated in models of respiratory syncytial virus infection (Lu et al., 2019), ischemia-reperfusion injury in allogeneic lung transplants (Pieróg et al., 2007), and ischemia-reperfusion-induced injury to skeletal muscle (Wang et al., 2016). This evidence concerns the gene MPO and respiratory syncytial virus infectious disease.